Verastem Slashes Staff After Mesothelioma Failure
This article was originally published in Scrip
Verastem Inc. is slashing its head count by 50%, or 20 employees, as the company continues to regroup after lead drug candidate VS-6063 failed to show an efficacy benefit for mesothelioma patients at an interim analysis in a Phase II clinical trial.
You may also be interested in...
Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.